Browse the evidence

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significantly greater weight loss than older anti-obesity medications (orlistat, phentermine/topiramate, naltrexone/bupropion) by targeting hypothalamic appetite regulation and delaying gastric emptying.

If lifestyle changes alone haven't worked, newer GLP-1 medications (like semaglutide or tirzepatide) are significantly more effective than older drugs, achieving 15-20% weight loss compared to 3-5% with older options. However, they are expensive, require weekly injections (mostly), and can cause gastrointestinal side effects. They are best considered for those with obesity-related comorbidities who have failed lifestyle interventions.

GLP-1 receptor agonists (semaglutide 2.4mg) and dual agonists (tirzepatide 15mg) produce significant, sustained weight loss (11.8% and 14.7-20.9% respectively) compared to placebo, but discontinuation leads to significant weight recurrence (approx. 2/3 of lost weight).

If you qualify (BMI ≥27 with comorbidity or ≥30), GLP-1 agonists like semaglutide (2.4mg weekly) or tirzepatide (15mg weekly) are highly effective, producing 12-21% weight loss. However, these are chronic treatments; stopping them leads to regaining ~2/3 of the weight. Discuss coverage and long-term commitment with your provider.

GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide) and dual/triple agonists induce T2D remission primarily through significant weight loss and reduction of ectopic fat, with some direct beta-cell protective effects.

If you have prediabetes or early Type 2 Diabetes and struggle with weight, GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) are highly effective at restoring normal blood sugar levels. These drugs work by reducing appetite and body weight, with some also having direct benefits on beta-cells. They are often used alongside lifestyle changes.

Semaglutide significantly reduces all-cause mortality and myocardial infarction risk in patients at increased risk of cardiovascular events, with high-certainty evidence.

If you are at high risk for heart issues, semaglutide is a proven treatment that lowers your risk of dying or having a heart attack. While you may experience stomach upset, these side effects are generally not serious and are outweighed by the life-saving benefits. Consult your doctor to see if this medication is appropriate for your specific risk profile.

Once-weekly subcutaneous semaglutide 2.4 mg, when combined with lifestyle interventions, produces clinically significant weight loss (average 14.9-16.0% body weight reduction) in adults with obesity or overweight with comorbidities, significantly outperforming placebo and daily liraglutide 3.0 mg.

If you have obesity or are overweight with a related health issue, once-weekly semaglutide 2.4 mg is a highly effective tool for weight loss when combined with diet and exercise. It works by mimicking a hormone that slows digestion and reduces appetite. You start with a low dose to minimize stomach upset, then increase it weekly until you reach the full dose. Expect significant weight loss (around 15%) over 6-8 months, which is much more than diet and exercise alone. Be aware of potential side effects like nausea, which usually fade, and avoid the medication if you have a specific family history of thyroid cancer.

Tirzepatide (5-15 mg) produces significantly greater weight loss, waist circumference reduction, and HbA1c improvement compared to placebo, insulin, and GLP-1 receptor agonists in adults with type 2 diabetes or obesity.

Tirzepatide is a highly effective treatment for weight loss and blood sugar control, outperforming existing GLP-1 drugs and insulin. It requires weekly injections and careful dose titration to manage gastrointestinal side effects like nausea.

For patients with Class I obesity (BMI 30–34.9 kg/m2), newer obesity management medications (OMM) such as tirzepatide and semaglutide provide total body weight loss (TBWL) efficacy equivalent to major metabolic bariatric surgeries (MBS) like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB), while offering superior safety and tolerability profiles.

If you have Class I obesity (BMI 30-34.9), you no longer need to choose between surgery and medication as your first step. Newer medications like tirzepatide and semaglutide can help you lose as much weight as major surgeries like gastric bypass, but with fewer risks and side effects. This makes medication a highly effective and safer first-line treatment for this specific group.

Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly (5-15 mg), significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity, outperforming placebo, GLP-1 receptor agonists (semaglutide, dulaglutide), and basal insulins.

Tirzepatide is a once-weekly injection approved for type 2 diabetes and obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to lower blood sugar and reduce appetite. Clinical trials show it leads to significant weight loss (up to 22% in obesity) and better blood sugar control than many existing medications, including standard GLP-1 drugs and insulin. Treatment starts at a low dose to manage side effects like nausea, which usually decrease over time.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significantly greater reductions in HbA1c and body weight compared to semaglutide 1 mg and basal insulins in adults with type 2 diabetes.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with type 2 diabetes, outperforming other common treatments like semaglutide and basal insulins in clinical trials.

GLP-1 receptor agonists and related incretin-based therapies are effective pharmacological interventions for obesity and type 2 diabetes, offering superior weight loss and cardiovascular benefits compared to previous treatments.

GLP-1 receptor agonists are a major advance in obesity treatment, offering significant weight loss and cardiovascular benefits. They work by mimicking gut hormones that regulate appetite and blood sugar. Consult a doctor to see if they are appropriate for you.

Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces systemic inflammation, measured by C-reactive protein (CRP), in adults with overweight or obesity compared to placebo.

If you have overweight or obesity, taking once-weekly semaglutide 2.4 mg significantly lowers your C-reactive protein (CRP), a key marker of systemic inflammation and cardiovascular risk. This benefit occurs alongside weight loss and is consistent regardless of your baseline BMI or diabetes status. The treatment involves a gradual dose escalation over 16 weeks to minimize side effects, followed by maintenance at 2.4 mg weekly for 68 weeks, combined with lifestyle changes.

Semaglutide 2.4mg weekly induces significantly greater weight loss (mean 14.9%) compared to lifestyle interventions alone (mean 2.4%) in adults without diabetes.

Semaglutide 2.4mg taken once weekly, combined with a modest caloric deficit, can lead to an average 15% body weight loss in people without diabetes. This is significantly more effective than lifestyle changes alone and helps counteract the biological drive to regain weight.

GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control primarily through delayed gastric emptying, reduced appetite, and central nervous system-mediated satiety pathways.

GLP-1 and dual agonists are highly effective for weight loss and blood sugar control, working by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize stomach upset, and increase gradually as tolerated. Expect significant weight loss (up to 20% in some trials) and improved glucose levels, but be prepared for potential gastrointestinal side effects like nausea.

Anti-obesity medications (AOMs) including orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide are effective for long-term weight management in adults with BMI ≥ 25 kg/m² who have failed non-pharmacological treatments.

If you have obesity and lifestyle changes haven't worked, talk to your doctor about FDA-approved anti-obesity medications. Drugs like semaglutide (once-weekly injection or daily pill) and liraglutide (daily injection) can help you lose significant weight. Start with a low dose to minimize stomach upset, and work with your provider to find the right medication for your specific health needs.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates superior weight loss efficacy compared to other currently available AOMs in phase 3 trials.

Tirzepatide is a new once-weekly injection that targets two hormones (GIP and GLP-1) to help with weight loss. In clinical trials, it led to an average 22.5% body weight loss over 72 weeks. It starts at a low dose to minimize side effects and can be increased up to 15 mg weekly. Talk to your doctor about whether this advanced option is right for you.

Targeting specific neural circuits in the brainstem and hypothalamus using peptide-based pharmacotherapies (e.g., GLP-1 mimics) is an effective strategy for inducing weight loss and treating obesity.

Consult a healthcare provider about GLP-1 based treatments if lifestyle changes alone are insufficient. These medications work by targeting brain circuits to reduce appetite and increase satiety, offering a biologically targeted approach to weight loss.

Weekly administration of semaglutide (2.4 mg) and tirzepatide (15 mg) produces substantially greater weight loss (9.6% and 13.1% respectively) compared to pre-existing anti-obesity medications (approx. 5% weight reduction).

If you have type 2 diabetes and obesity, current guidelines suggest trying lifestyle changes first. If that fails, newer injectable medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective at reducing body weight (around 10-13%) than older oral or injectable options (around 5%). These require a prescription and gradual dose titration to manage side effects.

Tirzepatide (15 mg) demonstrates superior weight loss efficacy compared to semaglutide (1 mg) in patients with type 2 diabetes, achieving 13.1% weight loss versus 9.7 kg (9.6%) for semaglutide 2.4 mg in direct comparison trials.

For patients with type 2 diabetes needing significant weight loss, tirzepatide (15 mg weekly) has shown higher weight loss percentages (13.1%) compared to semaglutide (1 mg weekly) in head-to-head trials. This requires a slow 20-week titration to manage side effects, which may impact adherence.

Tirzepatide (5-15 mg subcutaneous once weekly) produces substantial body weight reduction (up to 21%) in adults with or without type 2 diabetes, with efficacy superior to GLP-1 mono-agonists like semaglutide.

Tirzepatide is a highly effective, once-weekly subcutaneous injection for weight loss, approved for adults with obesity or overweight with weight-related conditions. It works by mimicking hormones (GLP-1 and GIP) that regulate appetite and blood sugar. Clinical trials show significant weight loss (up to 21%) in people without diabetes and up to 15% in those with type 2 diabetes. Common side effects like nausea and diarrhea are usually temporary and can be managed by starting with a low dose and increasing gradually. It is superior to older GLP-1 medications in weight reduction.

Semaglutide (2.4 mg/week) improves physical function and reduces body weight in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) can help you feel better, walk further, and lose weight. It is taken as a weekly injection, starting at a low dose to minimize side effects.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) significantly reduce body weight and improve glycemic control in patients with type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.

For individuals with obesity or type 2 diabetes, GLP-1 and GLP-1/GIP receptor agonists are highly effective treatments that promote significant weight loss and improve blood sugar control. These medications work by mimicking natural hormones to increase insulin, reduce glucagon, slow digestion, and decrease appetite. While they can cause gastrointestinal side effects like nausea, starting with a low dose and increasing it slowly helps manage these symptoms. They are particularly beneficial for those who have not achieved sufficient weight loss or cardiovascular risk reduction with lifestyle changes alone.

GLP-1 receptor agonists (GLP1RA) reduce body weight in humans primarily by reducing food intake, not by increasing energy expenditure.

GLP-1 medications like semaglutide and liraglutide work by reducing your appetite, not by speeding up your metabolism. This makes it easier to eat less, leading to significant weight loss (e.g., ~8.4 kg with liraglutide 3mg over 52 weeks). Focus on the reduction in food intake as the primary driver of weight loss.

GLP-1 receptor agonists reduce food intake and body weight in humans, with efficacy comparable to or rivaling bariatric surgery.

GLP-1 medications are effective for weight loss and may eventually rival bariatric surgery in efficacy. They offer a non-surgical option for treating obesity.

GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists improve metabolic health in obesity and type 2 diabetes by lowering BMI, improving insulin sensitivity, and potentially activating thermogenic fat.

GLP-1 and GLP-1/GIP agonists are powerful tools for treating obesity and type 2 diabetes. They work by reducing appetite and improving how your body handles insulin and fat. These drugs have been shown to lead to significant weight loss (over 20% in some cases) and improve heart health. They are often used alongside lifestyle changes like diet and exercise.